1146089-80-6

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 3-(6-bromopyridin-3-yl)oxyazetidine-1-carboxylate is used as a synthetic intermediate for the preparation of various organic compounds. Its bromopyridin-3-yl group and ester functionality can be utilized in various synthetic transformations, making it a valuable building block in organic synthesis.
Used in Medicinal Chemistry:
Tert-butyl 3-(6-bromopyridin-3-yl)oxyazetidine-1-carboxylate is used as a potential lead compound in the development of new pharmaceutical agents. Its unique structure and functional groups can be exploited to design and synthesize novel bioactive molecules with potential therapeutic applications.
Used in Research and Investigation:
Tert-butyl 3-(6-bromopyridin-3-yl)oxyazetidine-1-carboxylate is used as a research compound to study its chemical properties, reactivity, and potential applications. Its unique structure and functional groups make it an interesting target for further research and investigation in the fields of organic chemistry and medicinal chemistry.

Upstream product

• 55717-45-8 6-bromo-pyridin-3-ol 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1146089-90-8 3-[6-(4-methoxycarbonyl-3-fluorophenyl)pyridin-3-yloxy]azetidine-1-carboxylic acid tert-butyl ester 
• 1146089-99-7 3-[6-(4-methoxycarbonyl-3-methylphenyl)pyridin-3-yloxy]azetidine-1-carboxylic acid tert-butyl ester 
• 1287685-83-9 benzyl 4-(5-(1-(tert-butoxycarbonyl)azetidin-3-yloxy)pyridin-2-yl)piperazine-1-carboxylate 
• 1287684-99-4 benzyl 4-(5-(1-(4-isopropylbenzyl)azetidin-3-yloxy)pyridin-2-yl)-3-oxopiperazine-1-carboxylate 
• 1287684-98-3 1-(5-(1-(4-isopropylbenzyl)azetidin-3-yloxy)pyridin-2-yl)-4-(methylsulfonyl)piperazine 

Relevant academic research and scientific papers

A novel RET inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition and application thereof. In particular, the invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I said compound and a pharmaceutical composition thereof for the manufacture of a medicament, in particular for the treatment and prophylaxis and RET of diseases and disorders associated with irritable bowel syndrome.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.

AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.